Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Wassmann

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Annals of Hematology|March 4, 2003
Imatinib for relapsed BCR/ABL positive leukemiasO G Ottmann, B Wassmann, D Hoelzer
Der Internist|May 2, 2000
[Pancytopenia, hepatosplenomegaly and fever in a 49-year old patient]B Wassmann, G Seipelt, F Länger, et al.
Bone Marrow Transplantation|November 1, 1994
Microangiopathic hemolytic anemia and renal impairment following autologous bone marrow transplantation: a case of hemolytic uremic syndrome?B Wassmann, H Martin, S Elsner, et al.
Annals of Hematology|June 10, 1998
Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicinG Seipelt, W K Hofmann, H Martin, et al.
Bone Marrow Transplantation|September 1, 1996
Residual leukemia and immunomagnetic bead purging in patients with BCR-ABL-positive acute lymphoblastic leukemiaJ Atta, H Martin, J Bruecher, et al.
Experimental Hematology|December 1, 1995
Purging of peripheral blood stem cells yields BCR-ABL-negative autografts in patients with BCR-ABL-positive acute lymphoblastic leukemiaH Martin, J Atta, P Zumpe, et al.
Annals of Hematology|December 3, 2003
A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10)B Wassmann, N Gökbuget, U J Scheuring, et al.
Bone Marrow Transplantation|November 13, 2001
Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantationB Wassmann, S A Klein, U Scheuring, et al.
British Journal of Haematology|May 31, 2001
Older patients with high-risk fungal infections can be successfully allografted using non-myeloablative conditioning in combination with intensified supportive care regimensS Hermann, S A Klein, V Jacobi, et al.
Leukemia|September 13, 2003
Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatmentU J Scheuring, H Pfeifer, B Wassmann, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Annals of Hematology|March 4, 2003
Imatinib for relapsed BCR/ABL positive leukemiasO G Ottmann, B Wassmann, D Hoelzer
Der Internist|May 2, 2000
[Pancytopenia, hepatosplenomegaly and fever in a 49-year old patient]B Wassmann, G Seipelt, F Länger, et al.
Bone Marrow Transplantation|November 1, 1994
Microangiopathic hemolytic anemia and renal impairment following autologous bone marrow transplantation: a case of hemolytic uremic syndrome?B Wassmann, H Martin, S Elsner, et al.
Annals of Hematology|June 10, 1998
Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicinG Seipelt, W K Hofmann, H Martin, et al.
Bone Marrow Transplantation|September 1, 1996
Residual leukemia and immunomagnetic bead purging in patients with BCR-ABL-positive acute lymphoblastic leukemiaJ Atta, H Martin, J Bruecher, et al.
Experimental Hematology|December 1, 1995
Purging of peripheral blood stem cells yields BCR-ABL-negative autografts in patients with BCR-ABL-positive acute lymphoblastic leukemiaH Martin, J Atta, P Zumpe, et al.
Annals of Hematology|December 3, 2003
A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10)B Wassmann, N Gökbuget, U J Scheuring, et al.
Bone Marrow Transplantation|November 13, 2001
Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantationB Wassmann, S A Klein, U Scheuring, et al.
British Journal of Haematology|May 31, 2001
Older patients with high-risk fungal infections can be successfully allografted using non-myeloablative conditioning in combination with intensified supportive care regimensS Hermann, S A Klein, V Jacobi, et al.
Leukemia|September 13, 2003
Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatmentU J Scheuring, H Pfeifer, B Wassmann, et al.
Pageof 2